Compare Cassava Sciences Inc (FLNA) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Hyatt Hotels Corporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Hyatt Hotels Corporation trades at $159.3 (market cap $15.02B). The key difference: Hyatt Hotels Corporation is far larger — about 381.2× Cassava Sciences Inc's market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Hyatt Hotels Corporation for 148 Days on average.
| FLNA | H | |
|---|---|---|
Market Cap | $39.40M | $15.02B |
Volume | 759,018 | 842,340 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $202.09 |
52-Week Low | $0.68 | $135.42 |
Typical Hold Time | 37 Days | 148 Days |
Enterprise Value | -$43.28M | $18.93B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Hyatt Hotels (H) trades at $157.14, down 1.24% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows mixed fundamentals: revenue grew to $7.10B in 2025, but net income was a loss of $52M, and valuation ratios like a P/E of 194 appear elevated. Recent news highlights expansion efforts, including a loyalty collaboration with Delta Air Lines and new hotel openings, signaling growth initiatives amid operational challenges.
The outlook for H is cautious; analyst consensus is a Moderate Buy with a $197.77 price target, but high debt levels and volatile profitability pose risks. Upside depends on sustained revenue growth and margin improvement, while downside risks include economic sensitivity and execution delays in new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
